Company Overview
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Recent Developments
- Dec 2025 Revenue of $48.27M (-69.0% YoY); net profit $-196.45M.
- Trailing 12 Months Year-on-year growth — revenue +93.0%, earnings -1390.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -34.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -34.64% |
| 1 Year: | 93.00% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -1,390.89% |
Stock Price Performance
| 1 Year: | +54.75% |
| 6 Months: | -5.60% |
| 3 Months: | +2.39% |
| 1 Month: | -2.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.44 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -34.6% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMTX Immatics N.V. PHARMA | 9.44 | -5.16 | $1.44B | 0.00% | -35.05% | -47.80% | -34.64% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 18.58M | 4.74M | 5.19M | 19.76M | 7.61M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 53.96M | 57.86M | 59.82M | 58.64M | 73.68M |
| Operating Income | -35.37M | -53.13M | -54.63M | -38.88M | -66.06M |
| EBITDA | -37.46M | -68.08M | -47.38M | -32.17M | -54.77M |
| Interest Expense | 249.00K | 244.00K | 231.00K | 222.00K | 212.00K |
| Pretax Income | -40.85M | -71.35M | -50.67M | -35.56M | -57.76M |
| Tax Provision | -994.00K | -1.00M | -127.00K | 134.00K | 52.00K |
| Net Income | -39.85M | -70.35M | -50.55M | -35.70M | -57.81M |
| Diluted EPS | -0.33 | -0.58 | -0.42 | - | -0.43 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 172.83M | 54.00M | 155.84M | 48.27M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 142.88M | 155.72M | 194.45M | 230.28M |
| Operating Income | - | 29.95M | -101.72M | -38.62M | -182.02M |
| EBITDA | - | 50.04M | -88.93M | 34.46M | -185.09M |
| Interest Expense | - | 1.04M | 831.00K | 886.00K | 946.00K |
| Pretax Income | - | 42.04M | -96.99M | 21.35M | -198.44M |
| Tax Provision | - | 14.33M | -2.35M | 6.13M | -1.99M |
| Net Income | - | 27.70M | -94.65M | 15.22M | -196.45M |
| Diluted EPS | - | 0.55 | -1.18 | 0.14 | -1.61 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 407.82M | 509.96M | 696.15M | 562.34M |
| Current Assets | - | 377.15M | 449.37M | 629.55M | 504.01M |
| Cash & Equivalents | - | 148.52M | 218.47M | 236.75M | 345.92M |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.11M | 4.09M | 5.86M | 6.10M |
| Total Liabilities | - | 204.47M | 292.35M | 121.30M | 78.24M |
| Current Liabilities | - | 106.45M | 156.55M | 67.99M | 43.01M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 14.56M | 15.40M | 16.20M | 15.63M |
| Total Equity | - | 203.35M | 217.62M | 574.84M | 484.10M |
| Shares Outstanding | - | 76.67M | 84.66M | 121.55M | 134.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 100.13M | 18.23M | -158.03M | -176.63M |
| Investing Cash Flow | - | -209.79M | -31.39M | -152.39M | 204.79M |
| Financing Cash Flow | - | 123.71M | 84.52M | 319.68M | 97.35M |
| Capital Expenditure | - | -6.21M | -30.96M | -16.48M | -6.80M |
| Free Cash Flow | - | 93.92M | -12.73M | -174.51M | -183.43M |
| Net Change in Cash | - | 14.05M | 71.36M | 9.27M | 125.51M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | 17.3% | -188.4% | -24.8% | -377.1% |
| Net Margin % | - | 16.0% | -175.3% | 9.8% | -407.0% |
| ROE % | - | 13.6% | -43.5% | 2.6% | -40.6% |
| ROCE % | - | 9.9% | -28.8% | -6.1% | -35.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 16.36% | 22.37M | $192.79M |
| 2 | RTW Investments LP | 9.47% | 12.95M | $111.60M |
| 3 | Montanova Capital LLC | 8.19% | 11.19M | $96.46M |
| 4 | Perceptive Advisors Llc | 7.60% | 10.38M | $89.51M |
| 5 | Baker Bros. Advisors, LP | 6.96% | 9.51M | $81.96M |
| 6 | Jefferies Financial Group Inc. | 4.76% | 6.51M | $56.09M |
| 7 | Vestal Point Capital, LP | 4.52% | 6.17M | $53.23M |
| 8 | Sofinnova Investments, Inc. | 2.68% | 3.67M | $31.63M |
| 9 | Morgan Stanley | 1.60% | 2.19M | $18.85M |
| 10 | Citadel Advisors Llc | 1.33% | 1.81M | $15.64M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMTX
IMTX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5vTDBuRk8ydHlWZ2tVNHJIMTFaZGVRdlFXZ0w1b09uV1NMVmNyTlJDMndudzRaWWZYWl90SHVjR0dhaGNIU1dVWGlneXQ0OGVza2dTbloxakJ1LUFvdnI0a2RBdF9tQ1dZcnFEaWE4SnVxdUcwQUwwUUx3?oc=5" target="_blank">IMT…
Price-Driven Insight from (IMTX) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQLVVvdTg5TUh1WjQ0MGhPS0pSQmxHa1NCVTNLX1hmT1RwM3pXd1dFb0o4R0JhSUJqdHpYTV9GRTRuWWs1bVhZbERadExWTG1YenZiNEMxal9KSU5xSUUzU0xOQzdzNS1YTEZmNnRnVW11a0pfa0JRNVd2Y0hIcUZvM1NrTU5EUC03S0FWQy…
Why Immatics (IMTX) Is Down 5.4% After Mixed First‑Half 2026 Loss Trends And What's Next - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPNWgzOXgtUnB1YzNNRDhxM1VGOXg5eVJEOENCMnlRZ1EyRHBxMTNQRmNsQ3FjUnpiUWhwN2kyS1VOOHRfUG1fMEhBbDdqVmVMSEZfNXU5U2J6cXpaYXlsYkxjdVdnaVRaeG5ZQy1zV0hiQU9xc2hNcm1VeWxaME5hcngwZDQ4M18yTUxOcE…
Immatics N.V. (IMTX) Stock Analysis: A Deep Dive Into Its 103% Potential Upside - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOck1DYWJMekVBMFlmMDlMRVFMT3dmYzk4c0hfdWNVbUVma3BfYzBQY0ZGV3lmeGdlYVQySC1wSjFYVkJoV1JSNXp3UGdWU1FoOU42UzBMTHRtWlA2akIwRUYxR0VuRVFxeVdTbjBUYU1JZlhscFEycjZDZXdRZW04eGZZVVdKS3VMZnFmdV…
Immatics (IMTX): Baker Bros. group reports 9.5M-share, 7% ownership stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPaVJ6QVJ3ZXFxY1pPb3N4WWpKTXpHaHhEUHRNOE1BbDZ5eWotbGRKd3dRYkozTkp0S1VScTRVbGxNaFpfamtaZlVMSi1yd3E1T0s1Ukh2enZFX1lkWDJRempOdUZiNThZdVpHb3hpYVRMTTNJSHFXdjZZTFBTcG9uOERGNnJmM1M5QkRwdl…
Immatics (NASDAQ:IMTX) Shares Up 5.3% on Insider Buying Activity - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQcGpDaGlpYS00RHBQa21INUl0ZHVyS1hjUFR2RjRFa1NOQmdyNlkzSmQzNWNkUTBaQzVQSWQwWHpXQ3liYXVZN2lkTUpaQUp5akUzYUFkTG9XWHpCZldHNHowWG1FYnB3cVNpSTBLcUgzRjFqTEJIRm14VWFxZGdSY09FRkgtekduX2tyNm…
IMTX — Frequently Asked Questions
What is the current share price of Immatics N.V. (IMTX)?
As of 2026-09-19 21:16 PDT, Immatics N.V. (IMTX) trades at $9.44 on NasdaqCM. Its 52-week range is $5.09 to $11.87.
What is the market capitalisation of IMTX?
Immatics N.V. (IMTX) has a market capitalisation of $1.44B on NasdaqCM.
What is the P/E ratio of IMTX?
IMTX trades at a trailing price-to-earnings (P/E) ratio of -5.16. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.56.
What is the return on equity (ROE) of IMTX?
IMTX has a return on equity (ROE) of -47.80%. Its return on capital employed (ROCE) is -35.05%.
Is IMTX a good stock to buy?
This page provides a data-driven analysis of Immatics N.V. (IMTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.